| ￥3000 | |
| Z05314-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | >?95%?as?determined?by?Bis?Tris?PAGE? | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 48.68 kDa | ||||
| Apparent Molecular Weight | The protein migrates to 50-55 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 20mM PB, 500mM NaCl, 10% Glycerol. | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Fibronectin type III domain?containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC. |
| Synonyms | FNDC2; KIAA1866; MEL4B3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
